6-KThe Wire
Telix Pharmaceuticals Ltd files 6-K
Filed Apr 7, 2026 · 2mo ago · Accession 0001628280-26-023982
Plain English
Telix Pharmaceuticals Limited reported strong revenue growth in Q1 2026, driven by advancements in its therapeutics pipeline. The company filed an announcement with the Australian Securities Exchange on April 7, 2026, detailing these Q1 business highlights.
Filing details
- Company
- Telix Pharmaceuticals Ltd
- Ticker
- TLX
- CIK
- 2007191
- Form type
- 6-K
- Filing date
- Apr 7, 2026
- Report date
- Mar 31, 2026
- Document
- telix-6kforq1businessrelea.htm
- Size
- 287 KB
More from TLX
6-KThe WireJul 2, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSMay 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 23, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 20, 20266-KThe WireApr 14, 2026